Oxidative stress markers predict treatment outcomes in patients with generalized anxiety disorder treated with selective serotonin reuptake inhibitors

Lijun Cui, Jingjing Lu, Zhongxia Shen, Jielin Zhu, Huanxin Chen, Shenliang Yang, Shikai Wang, Xinhua ShenmedRxiv 2024 · DOI

Abstract

The etiology of generalized anxiety disorder (GAD) remains partially understood, though oxidative stress is increasingly implicated in its pathogenesis. This study investigated whether oxidative stress markers could predict treatment outcomes in GAD patients treated with selective serotonin reuptake inhibitors (SSRIs). Analyzing 101 GAD patients and 100 healthy controls, researchers measured eight markers—including malondialdehyde (MDA), lipid hydroperoxides (LPO), and various antioxidants—before and after an eight-week course of escitalopram or sertraline. Results indicated that GAD patients exhibit significantly higher levels of oxidative damage markers and lower antioxidant defenses compared to healthy controls. Notably, baseline MDA levels demonstrated a strong ability to predict treatment response (AUC = 0.804), suggesting that oxidative stress markers may serve as valuable clinical tools for personalizing anxiety treatment.

Introduction

Generalized Anxiety Disorder (GAD) is a chronic psychiatric condition characterized by persistent and excessive worry. While Selective Serotonin Reuptake Inhibitors (SSRIs) are the primary pharmacological intervention, clinical response varies significantly among patients. Currently, psychiatry lacks objective biological markers to predict which patients will benefit from SSRI therapy, relying instead on subjective clinical assessments.

Recent research has turned toward oxidative stress—an imbalance between the production of reactive oxygen species and the body's antioxidant defenses—as a potential factor in GAD. This study explores whether the "oxidative signature" of a patient can serve as a predictive biomarker for SSRI treatment success.

Methodology

The study utilized a prospective cohort design involving 101 patients diagnosed with GAD and 100 healthy controls (HCs).

Treatment and Assessment

Patients were treated with either escitalopram (n=52) or sertraline (n=49) for eight weeks. Clinical severity was measured using the Hamilton Anxiety Rating Scale (HAM-A) at baseline and at the end of the treatment period.

Biochemical Analysis

Serum levels of eight oxidative stress markers were measured via enzyme-linked immunosorbent assay (ELISA):

  • Oxidants (Damage Markers): Malondialdehyde (MDA), lipid hydroperoxides (LPO), cortisol, and nitric oxide (NO).
  • Antioxidants (Defense Markers): Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), and high-density lipoprotein (HDL).

Statistical analysis included Receiver Operating Characteristic (ROC) curves to determine the predictive power of baseline markers regarding treatment response (defined as a ≥50% reduction in HAM-A scores).

Key Findings

The Oxidative Profile of GAD

The study revealed a clear biological distinction between GAD patients and healthy individuals. At baseline, GAD patients showed significantly higher levels of MDA, cortisol, and LPO (p < .001) and significantly lower levels of protective antioxidants SOD, GSH-Px, and CAT (p < .001). Furthermore, higher baseline levels of MDA, LPO, and cortisol were positively correlated with the initial severity of anxiety symptoms.

SSRIs as Modulators of Oxidative Stress

Following eight weeks of SSRI treatment, patients showed more than just symptomatic improvement. Their biochemical profiles shifted: GSH-Px levels increased, while MDA and LPO levels decreased (all p < .05). This suggests that the therapeutic effect of SSRIs may be partially mediated by their ability to mitigate systemic oxidative stress.

MDA as a Predictive Biomarker

The most significant finding was the predictive value of Malondialdehyde (MDA). The Area Under the Curve (AUC) for baseline MDA levels in predicting the SSRI treatment response was 0.804 (p < .05). This indicates that patients with specific baseline oxidative stress profiles are statistically more likely to respond to standard SSRI protocols.

Discussion and Limitations

These findings suggest that GAD involves systemic physiological changes beyond the central nervous system. The ability of MDA to predict treatment response offers a potential path toward personalized medicine in psychiatry, where blood tests could help clinicians select the most effective interventions.

However, several limitations remain. The markers were measured in peripheral blood, which may not perfectly mirror oxidative processes within the brain. Additionally, while the sample size of 101 patients is robust for a preliminary study, larger multi-center trials are necessary to validate these markers across diverse populations. Future research should also investigate DNA damage markers, such as 8-OHdG, to determine if they offer even greater predictive precision.

Conclusion

Oxidative stress appears to play a significant role in the pathogenesis of Generalized Anxiety Disorder. Serum MDA levels, in particular, show promise as a biological marker for predicting how well a patient will respond to SSRI treatment. Integrating these biochemical assessments into clinical practice could eventually reduce the "trial and error" approach currently common in anxiety treatment.

Summary updated

Abstract

Abstract Introduction The etiology of generalized anxiety disorder (GAD) has not been fully understood, and oxidative stress may potentially contribute to its pathogenesis. However, there is no published evidence concerning the possible influence of oxidative stress on antidepressant treatment outcomes. This study investigated the ability of oxidative stress markers to predict treatment outcomes in GAD patients treated with selective serotonin reuptake inhibitors (SSRIs). Methods One hundred-one GAD patients and 100 healthy controls (HCs) were included in this study. The 101 GAD patients were selected for treatment with escitalopram (n=52) or sertraline (n=49) for eight weeks. Hamilton Anxiety Rating Scale (HAM-A) assessments were conducted before and after treatment. The serum levels of eight oxidative stress makers, malondialdehyde (MDA), lipid hydroperoxides (LPO), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), cortisol, high-density lipoprotein (HDL), and nitric oxide (NO) were measured using enzyme-linked immunosorbent assays (ELISA) before and after SSRI treatment in GAD patients and at the time of HCs enrollment. Results The serum levels of MDA, cortisol, and LPO were higher in GAD patients than in HCs (all p&lt;.001 ), while SOD, GSH-Px, and CAT were lower than in HCs (all p&lt;.001 ). The baseline MDA, LPO, NO, and cortisol levels were positively correlated with anxiety severity, while GSH-Px was negatively correlated. After eight weeks of SSRI treatment, the GSH-Px levels increased, and MDA and LPO decreased (all p&lt;.05 ). Alterations in MDA levels co-varied with changes in anxiety measures (all p&lt;.05 ). The ability of the receiver operating characteristic (ROC) area of the baseline MDA levels to predict the SSRI endpoint treatment response was 0.804 ( p&lt;.05 ). Conclusion The pathogenesis of GAD might involve oxidative stress. Moreover, serum MDA levels might predict treatment response to SSRIs. However, more research is warranted to confirm these findings.
BibTeX
@misc{cui2024oxidative,
  author = {Lijun Cui and Jingjing Lu and Zhongxia Shen and Jielin Zhu and Huanxin Chen and Shenliang Yang and Shikai Wang and Xinhua Shen},
  title = {{Oxidative stress markers predict treatment outcomes in patients with generalized anxiety disorder treated with selective serotonin reuptake inhibitors}},
  year = {2024},
  doi = {10.1101/2024.09.07.24313247},
  howpublished = {medRxiv},
}
Figure